CA2522329A1 - Inhibiteurs de coronavirus - Google Patents

Inhibiteurs de coronavirus Download PDF

Info

Publication number
CA2522329A1
CA2522329A1 CA002522329A CA2522329A CA2522329A1 CA 2522329 A1 CA2522329 A1 CA 2522329A1 CA 002522329 A CA002522329 A CA 002522329A CA 2522329 A CA2522329 A CA 2522329A CA 2522329 A1 CA2522329 A1 CA 2522329A1
Authority
CA
Canada
Prior art keywords
peptide
seq
ile
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002522329A
Other languages
English (en)
Inventor
Peter S. Kim
Debra Eckert
Victor M. Garsky
Roger M. Freidinger
Romas Geleziunas
Antonello Pessi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2522329A1 publication Critical patent/CA2522329A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002522329A 2003-04-14 2004-04-12 Inhibiteurs de coronavirus Abandoned CA2522329A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US46310003P 2003-04-14 2003-04-14
US60/463,100 2003-04-14
US46719003P 2003-04-30 2003-04-30
US60/467,190 2003-04-30
US47886003P 2003-06-16 2003-06-16
US60/478,860 2003-06-16
US47942903P 2003-06-18 2003-06-18
US47943003P 2003-06-18 2003-06-18
US60/479,429 2003-06-18
US60/479,430 2003-06-18
PCT/US2004/011210 WO2005002500A2 (fr) 2003-04-14 2004-04-12 Inhibiteurs de coronavirus

Publications (1)

Publication Number Publication Date
CA2522329A1 true CA2522329A1 (fr) 2005-01-13

Family

ID=33568933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002522329A Abandoned CA2522329A1 (fr) 2003-04-14 2004-04-12 Inhibiteurs de coronavirus

Country Status (3)

Country Link
EP (1) EP1615610A2 (fr)
CA (1) CA2522329A1 (fr)
WO (1) WO2005002500A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111349150A (zh) * 2020-03-24 2020-06-30 北京中科微盾生物科技有限责任公司 一种抑制新型冠状病毒的多肽及其用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186575A1 (en) * 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN107022008B (zh) * 2016-01-30 2021-04-23 山西锦波生物医药股份有限公司 广谱地抑制人类冠状病毒感染的多肽及其应用
WO2021183463A1 (fr) * 2020-03-09 2021-09-16 President And Fellows Of Harvard College Compositions et méthodes pour traiter du coronavirus
CN111471088B (zh) * 2020-04-21 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制sars-cov-2感染的多肽、组合物及其用途
US11767353B2 (en) * 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
EP4281096A1 (fr) * 2021-01-22 2023-11-29 Decoy Therapeutics Inc. Procédés et compositions pour traiter des infections
BR112023019837A2 (pt) * 2021-03-30 2023-11-07 Baylor College Medicine Métodos e composições para inibição de proteína com base em polipeptídeo de alta potência
CN113072623B (zh) * 2021-04-28 2022-10-14 苏州大学 一种靶向SARS-CoV-2 N蛋白的干扰肽的制备方法及应用
CN114437184B (zh) * 2021-08-16 2022-11-18 中国科学院微生物研究所 一种抗新型冠状病毒的多肽及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111349150A (zh) * 2020-03-24 2020-06-30 北京中科微盾生物科技有限责任公司 一种抑制新型冠状病毒的多肽及其用途
CN111349150B (zh) * 2020-03-24 2021-02-09 北京中科微盾生物科技有限责任公司 一种抑制新型冠状病毒的多肽及其用途

Also Published As

Publication number Publication date
WO2005002500A2 (fr) 2005-01-13
EP1615610A2 (fr) 2006-01-18
WO2005002500A3 (fr) 2006-10-05

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
RU2236865C2 (ru) Гибридные полипептиды с улучшенными фармакокинетическими свойствами
TWI341844B (en) Hiv fusion inhibitor peptides with improved biological properties
Tian et al. Structure− affinity relationships in the gp41 ELDKWA epitope for the HIV‐1 neutralizing monoclonal antibody 2F5: effects of side‐chain and backbone modifications and conformational constraints
KR20000005429A (ko) 비수지성 주쇄 펩티드 담체
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
EP2858661B1 (fr) Hélices hybrides stabilisées antivirales
JP2007528422A (ja) 自己免疫疾患に関与する自己抗原および非自己抗原の同定
CA2522329A1 (fr) Inhibiteurs de coronavirus
US20070219136A1 (en) Methods and compositions for treating inflammatory disorders
CA2135278C (fr) Peptide pour la stimulation des lymphocites t cytotoxiques specifiques au virus de l'hepatite c
PT1797112E (pt) Inibidores do vírus da hepatite c
WO2022202816A1 (fr) Peptide et composition contenant un peptide
JPH08504090A (ja) 抗−ネコ免疫不全ウイルス(fiv)ワクチン
AU2021360898A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2021200800A1 (fr) Vaccin pour la prévention ou le traitement d'une infection à coronavirus ou de symptômes associés à une infection à coronavirus
ES2551699T3 (es) Composiciones, procedimientos y kits
US10328143B2 (en) Hemagglutinin-binding peptide
EP0767678A1 (fr) Compositions de proteines de transactivation du virus d'immunodeficience humaine
US20220125913A1 (en) SYNTHETIC PEPTIDES, AMINO-ACID SEQUENCES, AND COMPOSITIONS USEFUL FOR SARS-CoV-2 DETECTION AND COVID-19 PREVENTION
JPH02502637A (ja) 合成抗むしばワクチン
WO2021260176A1 (fr) Épitopes synthétiques de bêta-coronavirus
CA2372569A1 (fr) Composition de support d'immunogene de polypetide d'heterodimere et son procede d'utilisation
AU2002332701A1 (en) Methods and compositions for treating inflammatory disorders

Legal Events

Date Code Title Description
FZDE Discontinued